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Mutations in GBA2 Cause Autosomal-Recessive
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Autosomal-recessive cerebellar ataxia (ARCA) comprises a large and heterogeneous group of neurodegenerative disorders withmore than
20 different forms currently recognized, many of which are also associated with increased tone and some of which have limb spasticity.
Gaucher disease is a lysosomal storage disease resulting from a defect in the enzyme acid b-glucosidase 1. b-glucosidase 2 is an enzyme
with similar glucosylceramidase activity but to date has not been associated with a monogenic disorder. We studied four unrelated
consanguineous families of Tunisian decent diagnosed with cerebellar ataxia of unknown origin. We performed homozygosity mapping
and whole-exome sequencing in an attempt to identify the genetic origin of their disorder. We were able to identify mutations respon-
sible for autosomal-recessive ataxia in these families within the gene encoding b-glucosidase 2, GBA2. Two nonsense mutations
(c.363C>A [p.Tyr121*] and c.1018C>T [p.Arg340*]) and a substitution (c.2618G>A [p.Arg873His]) were identified, probably resulting
in nonfunctional enzyme. This study suggests GBA2 mutations are a cause of recessive spastic ataxia and responsible for a form of
glucosylceramide storage disease in humans.Autosomal-recessive cerebellar ataxias (ARCA) belong
to the large group of disorders known as the inherited
ataxias.1 More than 20 different forms of ARCA are
currently recognized.2 Symptoms start in childhood
and include balance abnormalities, incoordination, and
dysarthria. Cerebellum and/or spinocerebellar tracts are
involved.3,4 Many of these individuals with recessive
ataxia can additionally present with increased tone in
the limbs and some, often later in the disease, develop
pronounced limb spasticity with clinical signs such as
the Hoffman sign and have extensor planters. These
individuals and families are often called spastic ataxias.5
Five main pathogenic mechanisms may be distinguished:
defective DNA repair, abnormal protein folding and
degradation, channelopathies, and mitochondrial and
metabolic defects.6 Metabolic ataxias include lipid metab-
olism, peroxysomal, and storage diseases.6 Althoughmuta-
tions in a number of genes have been identified as causes
of ARCA, there are still many families and individuals
remaining with an unknown etiology.
In this study, we performed homozygosity mapping
and whole-exome sequencing in an attempt to identify
the genetic origin of autosomal-recessive ataxia in three
Tunisian families. This work was approved by the local
ethics committee and by the Office of Human Subjects
Research at the National Institutes of Health and all
affected individuals gave informed consent. We initially
studied three unrelated consanguineous families (C, E,1Molecular Genetics Section, Laboratory of Neurogenetics, National Institu
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The Americand I) of Tunisian decent in which seven individuals
were previously diagnosed with autosomal-recessive cere-
bellar ataxia. All affected individuals presented with child-
hood- or juvenile-onset cerebellar ataxia and brisk tendon
reflexes as discussed below. Blood was collected from
the affected individuals and six unaffected members of
families C, E, and I. The pedigrees of these families are
shown in Figure 1 and the clinical features are summarized
in Table 1. Genomic DNA was extracted from peripheral
blood lymphocytes by standard protocols. Linkage to
16 known loci for cerebellar ataxia has been previously
excluded in these families and the Friedreich ataxia expan-
sion was not detected.7
High-density SNP genotyping is a rapid and effective
method for mapping autozygous regions of the genome,8
so we undertook genome-wide SNP genotyping in all
available affected and unaffected individuals belonging
to families C, E, and I. Genotyping was performed with
the OmniExp-12,v1.0 DNA Analysis BeadChip (Illumina
Inc., San Diego, CA) according to the manufacturer’s
instructions. Because the families studied were highly
consanguineous, SNP array data was subjected to homozy-
gosity mapping with the Homozygosity Mapper software
by using only homozygous stretches of 15 alleles or
longer.9 For each family, we searched for shared homozy-
gous regions present among the affected individuals
and absent within the unaffected family members.
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Figure 1. Pedigrees of Four Families with ARCA
Affected family members are shaded. Males are represented by squares, females are represented by circles. Mutation status is denoted as
follows: WT, wild-type; mt, mutant.chromosome 9 (Figure S1 available online), spanning from
rs3936927 (chr9: 31,066,983 bp) to rs4646770 (chr9:
38,383,171 bp); notably, although disease in each of the
families segregated with this region, the genotypes
observed between families E and I were identical, suggest-
ing a shared common founder. APTX (MIM 606350),
a gene mutated in ataxia with oculomotor apraxia type 1
(AOA1 [MIM 208920]), was present in this candidate
region, but Sanger sequencing of APTX in the index indi-
viduals did not reveal mutations.
In an attempt to rapidly identify the underlying genetic
mutation, we performed whole-exome sequencing on the
DNA of each of the seven affected individuals belonging
to families C, I, and E according to the Nimblegen protocol
(Nimblegen v2.0, Roche Nimblegen, Indianapolis, IN).
Prior to sequencing, DNA templates were bridge amplified
to form clonal clusters inside a flowcell via the cBot cluster
generation process. The flowcells were then loaded into
the next-generation sequencer Illumina HiSeq 2000.
Paired end sequence reads were aligned with BWA against
the reference human genome (UCSC hg18).10 Duplicate246 The American Journal of Human Genetics 92, 245–251, Februaryread removal, format conversion, and indexing were
performed with Picard. The Genome Analysis Toolkit
was used to recalibrate base quality scores, perform
local realignments around possible indels, and to call and
filter the variants.11,12 Overall, more than 200 million
sequencing reads were produced for each sample, covering
more than 12 billion bases. Approximately 98% of these
were aligned to the human reference genome (hg18). On
average, 92% of exome capture baits had at least 103
depth and 87% at least 303 depth. Variants previously
identified in the 1000 Genomes project or within neuro-
logical normal control exome sequence within the same
laboratory were excluded. VCF tools were used to annotate
gene information for the remaining novel variants.11
Single-nucleotide variants that are nonsynonymous, stop
loss or gain, or within essential splice sites and indels
that were nonreference homozygous and shared among
affected family members were prioritized as potential
candidates for causal variants. These prioritized, poten-
tially novel shared protein coding variants were then
visually inspected with the Integrative Genomics Viewer7, 2013
Table 1. Clinical Data Summary
Family C E I K
ID C.IV:2 C.IV:3 E.IV:2 E.IV:3 I.IV.1 I.IV.2 I.IV:3 K.IV.3 K.IV.4 K.IV:5
Gender M M M F F F M F M M
Initial cerebellar signs GA GA,D,Ny GA,D,Ny GA GA,D,Ny GA GA GA GA GA
Limb ataxia P P P P P P P N/A P P
Age at onset (years) 4 4 10 8 5 3 6 14 15 15
Age at last exam (years) 35 33 41 37 25 25 12 32 34 40
DD (years) 31 29 31 29 20 22 6 18 19 25
ICARS score/100 36 32 53 28 21 10 6 N/A 33 29
ICARS subsection scoresa 12, 22, 2, 0 6, 14, 2, 0 21, 22, 4, 6 6, 22, 0, 0 9, 10, 1, 1 19, 11, 4, 0 2, 4, 0, 0 N/A 12, 17, 4, 0 12, 15, 2, 0
ICARS score/DD 1.16 1.1 1.7 0.97 1.05 1.43 1 N/A 1.74 1.16
TR knee brisk brisk brisk brisk brisk brisk brisk brisk brisk brisk
Ankle brisk brisk brisk brisk brisk brisk brisk brisk brisk brisk
Pyr S Babinski P P P P P P P P P P
Spasticity P P P P P P A P P P
DSD position error A P P P P P P P P P
Vibration sense P A P A N/A N/A N/A N/A N/A N/A
Distal limb amyotrophy A A A A A A P N/A A A
Skel. def. PC A A PC PC A A A A A A
Scoliosis P A P A A A A A A A
Sphincter disturbance A A P A A A A N/A A P
EMG at last exam neurogenic
plot
neurogenic
plot
neurogenic
plot
neurogenic
plot
N/A N/A severe axonal
sensory motor
neuropathy
axonal sensory
neuropathy
severe axonal
sensory motor
neuropathy
severe sensory
neuropathy
ENG central
vestibular
syndrome
central
vestibular
syndrome
central
vestibular
syndrome
central
vestibular
syndrome
N/A N/A N/A N/A N/A N/A
EP SEP N/A N/A N/A N/A Abn Abn N/A N/A N/A Abn
VEP N/A N/A N/A N/A N N N/A N N/A Abn
AEP N/A N/A N/A N/A N/A N/A N/A N N/A N
Cholesterol N N N N N/A N/A N/A N N/A N
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248 The American Journal of Human Genetics 92, 245–251, February(IGV).12 After filtering to identify potentially novel vari-
ants, less than 15 homozygous coding variants and less
than 25 homozygous indels were left per family.
In both families E and I, the same homozygous single-
nucleotide change (c.1018C>T) was identified in exon 5
of GBA2, leading to a stop codon formation (p.Arg340*)
with a predicted premature protein termination. In family
C, another homozygous variant (c.2618G>A) was found in
exon 17 of GBA2 resulting in the substitution of arginine
for histidine at residue 873 (p.Arg873His). This variant
is predicted to alter protein structure with Polyphen2
software analysis and affect a conserved residue (Fig-
ure 2). Nucleotide and protein positions of identified vari-
ants in GBA2 are based on RefSeq accession numbers
NM_020944.2 and NP_065995.1 from the National Center
for Biotechnology Information. Variant positions within
the cDNA are numbered with the A of the translation initi-
ation codon as position 1. Sanger sequencing of these
exons was performed with ABI BigDye Terminator Cycle
Sequencing Kit on an ABI 3730 sequencer. This verified
that these variants segregated with disease within the
families and further showed that none of these variants
were present in 50 Tunisian neurologically normal
controls or in 330 African, European, and Asian controls
from the Human Gene Diversity Panel (HGDP). We inter-
preted these results to strongly suggest GBA2 mutations
as the cause of ataxia in these families.
Next, we screened 21 Tunisian individuals diagnosed
with cerebellar ataxia of unknown origin. These samples
were exome sequencing with the Truseq exome enrich-
ment protocol according to the manufacturer’s instruc-
tions (Illumina, San Diego, CA). Alignment and variant
calling was performed as described above. A third homozy-
gous variant, c.363C>A, was identified in exon 2 of GBA2
in one of the samples (sample ID# Tun_12167) leading to
a stop codon formation (p.Tyr121*) predicted to cause
a very early truncation of the protein. This variant was
absent in 50 Tunisian neurologically normal controls and
in 330 controls from HGDP. It affects an amino acid highly
conserved across species (Figure 2). Further investigation
revealed two additional affected family members and this
variant demonstrated segregation with disease (family K)
(Figure 1).
The initial clinical presentation was progressive cere-
bellar ataxia in all affected individuals (six males and
four females). Onset was during childhood or early adult-
hood with kinetic and static cerebellar ataxia as the pre-
senting feature associated with cerebellar dysarthria. Three
of the individuals exhibited head tremor (K.IV:5, K.IV.4,
I.IV:3). All individuals developed a pyramidal syndrome
that consisted of spasticity in the lower limbs, brisk
reflexes, extensor plantars, and Hoffman sign. In one indi-
vidual, there was also external ophthalmoparesis with
a jerky pursuit and slow saccades. Pes cavus and scoliosis
were present in three of the individuals. One affected indi-
vidual also exhibited mild intellectual disability (E.IV:2).
The course of the disease was slowly progressive with an7, 2013
Figure 2. GBA2 Mutations Detected
Illustration of GBA2, which comprises 17 exons. The three mutations identified are located in exons 2, 5, and 17. In the middle portion
of the figure, sequence chromatograms are shown for each of the different mutations identified. Amino acid alignment via ClustalW is
shown in the lower portion of the figure and illustrates the sequence conservation across species.international cooperative ataxia rating scale (ICARS) score/
disease duration nearing 1 to 1.5.
With disease progression, affected individuals developed
an axonal sensory or sensory-motor neuropathy confirmed
by nerve conduction studies. The neuropathy was variable
in type and in severity. Cerebral and spinal MRI were
normal in most of the individuals. However, in individual
K.IV:3, the MRI showed global cerebral, cerebellar, corpus
callosum, and spinal cord atrophy. No abnormalities
were noted in blood sugar, vitamin A, cholesterol, triglyc-
erides, CK, AFP levels, lipid or protein electrophoresis, or
electrocardiogram in all screened individuals. We noted
normal or subnormal vitamin E levels in the individuals.
Individual I.IV:3 presented hepatomegaly, a frequently
observed clinical feature in type 1 Gaucher disease,13 but
other Gaucher features were absent in this and the other
affected individuals. The overall phenotype of these
Tunisian individuals is typical of the known recessive
ataxias, with the addition of pathological spasticity and
an axonal neuropathy.
Gaucher disease (MIM 606463) is the most common
lysosomal storage disease. It results from a defect in the
acid b-glucosidase 1 leading to the accumulation of glyco-
sylceramide in lysosomes of macrophages in different
organs, typically involving spleen, kidney, lungs, brain,The Americand bone marrow;14 neuronopathic forms of Gaucher
disease include progressive neurodegenerative disease.
b-glucosidase 2, which harbors similar glucosylceramidase
activity to b-glucosidase 1, is encoded by GBA2 (MIM
609471) and is not deficient in individuals with Gaucher
disease.15 b-glucosidase 2 cleaves the sphingolipid gluco-
sylceramide into glucose and ceramide.16 Degradation of
glucosylceramide by b-glucosidase 2 leads to further meta-
bolism of the generated ceramide to sphingomyelin.15
b-glucosidase2 is aubiquitous enzymedetected inall tissues
and expressed maximally in brain, heart, skeletal muscle,
kidney, and placenta.17 It is present in the endoplasmic
reticulum (ER)16 and/or in the plasma membrane.15,18
Nonfunctional copies of GBA2 would lead to the accumu-
lation of glycolipids and an ER storage disease.16
The tissue distribution of GBA2 mRNA is different
between human and mice. The mouse Gba2 mRNA is
abundant in the testis but not the human mRNA.16 Gba2
knockout mice display misshapen spermatozoa leading
to an impaired fertility.16 However, one of our individuals
(Tun_12167) has three children, which confirms that the
glycosylceramide metabolism is less important in sper-
matogenesis in humans15 and suggests that b-glucosidase
2 may play a different role in humans. Homozygous
Gba2 knockout mice showed no obvious neurologicalan Journal of Human Genetics 92, 245–251, February 7, 2013 249
signs,16 although it is worth noting that the Gba2
knockout mice lacked only exons 5 to 10 and retained
50% of normal glucosidase activity. We hypothesize that
the accumulation of glucosylceramides in the ER and/or
plasma membrane did not reach a critical threshold
necessary to drive neurological symptoms. It has also
been shown that the Gba2 activity increases more than
3-fold during the neuronal differentiation19 and suggested
that the accumulation of glucosylceramides in the ER of
neuronal cells would change calcium homeostasis and
lead to neurological symptoms.20
In summary, we describe families where ataxia was
the presenting feature, but later, spasticity became very
pronounced involving initially the lower limbs and later
also the upper limbs. All affected individuals were homozy-
gous for three different mutations in GBA2. Two of these
(p.Arg340* and p.Tyr121*) are nonsense mutations leading
to a protein truncated by 67% and 86%, respectively. The
resulting enzyme is very likely to be nonfunctional. The
third mutation is a substitution (p.Arg873His) occurring
within the COOH-terminal (residues 500–886), a region
apparently very conserved across different species imply-
ing its importance in the function of the protein.17 Thus,
we have shown that mutations in GBA2 are a likely cause
of this disorder. The mutation mechanism is likely to be
loss of function which, based on mouse work, will lead
to an accumulation of glucosylceramide and subsequently
the clinical phenotype.Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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